REDWOOD CITY, Calif.--(BUSINESS WIRE)--Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today that Tito A. Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and CoFounder, will participate in a panel discussion on immuno-oncology (IO) during the 9th Annual Biotech Showcase Conference on Wednesday, January 11, 2017, at 11:00a.m. Pacific Time.
The panel, titled “The Overflowing IO Buffet: Next Gen IO Antibodies, Oncolytic Viruses, Bispecifics, Adoptive Cell Therapies and Oral Immunometabolism / Immuno-Epigenetic Agents,” will be held at the Hilton San Francisco Union Square in Continental Room 2.
About Atreca, Inc.
Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atreca’s proprietary Immune Repertoire Capture® technology profiles a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates with the objective of enhancing engagement of the human immune response in cancer treatment and other indications, thus optimizing therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.